Eyeworld

Indications and Usage LACRISERT ® is indicated in patients with moderate to severe Dry Eye syndromes, including keratoconjunctivitis sicca. LACRISERT ® is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT ® is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions. Important Safety Information LACRISERT ® is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose. Instructions for inserting and removing LACRISERT ® should be carefully followed. If improperly placed, LACRISERT ® may result in corneal abrasion. Because LACRISERT ® may cause transient blurred vision, patients should be instructed to exercise caution when driving or operating machinery. Patients should be cautioned against rubbing the eye(s) containing LACRISERT ® . The following adverse reactions have been reported, but were in most instances, mild and temporary: Transient blurring of vision, Ocular discomfort or irritation, Matting or stickiness of eyelashes, Photophobia, Hypersensitivity, Eyelid edema, and Hyperemia. Only Dissatisfied Patients Need Apply * In most patients, one LACRISERT ® placed into each eye once daily is effective in providing all-day symptom relief. Some patients may require twice-daily use for optimal results. Once a Day.* Continuous Lubrication. Ongoing Protection. References: 1. LACRISERT [package insert] Madison, NJ: ATON Pharma, 2009 2. Hill J. Slow release artificial tear inserts in the treatment of dry eyes in patients with rheumatoid arthritis. Br J Ophthalmol. 1989;73:151-154. 3. Katz JI, Kaufman HE, Breslin C, Katz IM. Slow-release artificial tears and the treatment of keratitis sicca. Ophthalmology. 1978;85:787-793. 4. Koffler BH, McDonald M, Nelinson D, Improved signs and symptoms and quality of life with dry eye syndrome: hydroxypropyl cellulose ophthalmic insert patient registry. Eye Contact Lens. 2010;3:170-176. 5. Wander A, Koffler B. Extending the duration of tear film production: review and retrospective case series study of the hydroxypropyl cellulose ophthalmic insert. Ocul Surf. 2009;7(3e):154-162. Please see Brief Summary of Prescribing Information on the adjacent page. For patients seeking improvement in comfort and satisfaction: 2,3,4 Continuous lubrication, starting day 1. 1,2,3 Provides ongoing ocular surface protection, long term. 5 s Results of a large multicenter registry study of over 400 patients showed significant reduction (p<0.05) in frequency and severity of dry eye symptoms after just one month of therapy with LACRISERT ®4 s 53% of patients felt that LACRISERT ® improved the effectiveness of their existing therapy including artificial tears 4 In moderate to severe dry eye syndromes ATON Pharma, a Division of Valeant Pharmaceuticals North America LLC © 2011, ATON Pharma Madison, NJ 07940 LAC012-0211EW LAC012-0211_EyeWorld_Ad.indd 1 3/8/11 4:10 PM

• Cover